Basilea Pharmaceutica has secured up to USD 159 million in non-dilutive funding through BARDA to develop the novel antibiotic ceftibuten-ledaborbactam etzadroxil for treating complicated urinary tract infections.

Information on the Target

Basilea Pharmaceutica Ltd, based in Allschwil, Switzerland, is a commercial-stage biopharmaceutical company dedicated to developing treatments for severe bacterial and fungal infections. Recently, the company announced a significant advancement in its product portfolio with the acquisition of global rights to the novel oral antibiotic, ceftibuten-ledaborbactam etzadroxil, from Venatorx Pharmaceuticals, Inc. This combination, which consists of a beta-lactam and a beta-lactamase inhibitor, is aimed specifically at addressing complicated urinary tract infections (cUTIs), including pyelonephritis.

The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services, has novated a contract to Basilea to support the antibiotic's development. Through this contract, Basilea will receive non-dilutive funding of up to USD 159 million contingent upon reaching specific milestones, alongside an immediate commitment of USD 6 million.

Industry Overview in Switzerland

The biopharmaceutical industry in Switzerland is recognized for its innovation and robust research capabilities. The country is home to several leading pharmaceutical companies and biotech firm